Please assess the completion status of the following clinical trial:

Trial Title: iLux Treatment for Meibomian Gland Dysfunction (MGD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years and older of any gender or race~2. Provision of written informed consent prior to study participation~3. Willingness and ability to return for all study visits~4. A positive history of self-reported dry eye symptoms for three months prior to the study using the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire, and a score of \> 6.~5. Need for regular use of artificial tears, lubricants, or rewetting drops in both eyes~6. Evidence of meibomian gland (MG) obstruction, based on a total meibomian gland secretion score of \< 12 out of a maximum score of 45, for 15 glands (5 nasal, 5 medial, 5 temporal) of the lower eyelid of each eye. Glands expressed \& graded from 0 to 3 (0 = no secretion, 1 = inspissated, 2 = cloudy, 3 = clear liquid).~Exclusion Criteria:~1. History of ocular surgery including intraocular, oculo-plastic, corneal or refractive surgery within 1 year~2. Ocular trauma or herpetic keratitis within the previous 3 months~3. Cicatricial lid margin disease identified via slit lamp examination, including pemphigoid, symblepharon, etc.~4. Active ocular infection (e.g., viral, bacterial, mycobacterial, protozoan, or fungal infection of the cornea, conjunctiva, lacrimal gland, lacrimal sac, or eyelids including a hordeolum or stye)~5. Active ocular inflammation or history of chronic, recurrent ocular inflammation within prior 3 months (e.g. retinitis, macular inflammation, choroiditis, uveitis, iritis, scleritis, episcleritis, keratitis)~6. Ocular surface abnormality that may compromise corneal integrity (e.g., prior chemical burn, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal fluorescein staining, or map dot fingerprint dystrophy~7. Lid surface abnormalities (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis) that affect lid function in either eye~8. Anterior blepharitis (staphylococcal, demodex or seborrheic grade 3 or 4)~9. Ocular trauma, chemical burns, or limbal stem cell deficiency~10. Systemic disease conditions that cause dry eye (e.g., Stevens-Johnson syndrome, vitamin A deficiency, rheumatoid arthritis, Wegener's granulomatosis, sarcoidosis, leukemia, Riley-Day syndrome, systemic lupus erythematosus, Sjogren's syndrome)~11. Women who are pregnant, nursing, or not utilizing adequate birth control measures~12. Individuals who have either changed the dosing of systemic or ophthalmic medication within the past 30 days prior to screening or who are unable or unwilling to remain on a stable dosing regimen for the duration of the study~13. Individuals using isotretinoin (Accutane) within 1 year, cyclosporine-A (Restasis) within 2 months, or topical medications other than non-preserved artificial tears within 2 weeks.~14. Individuals using another investigational device or agent within 30 days of study participation~15. Contact lens wearers or individuals who have worn contact lenses in the last 30 days or anticipate wearing contact lenses during this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- iLux 2020 System (Type: EXPERIMENTAL): Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete